Peptide-metal nanohybrids (PMN): Promising entities for combating neurological maladies.

Autor: Kour A; Institute of Nano Science and Technology, Mohali, Punjab 140306, India; University Institute of Pharmaceutical Sciences, Punjab University, Chandigarh 160014, India., Panda HS; Institute of Nano Science and Technology, Mohali, Punjab 140306, India., Singh IR; Institute of Nano Science and Technology, Mohali, Punjab 140306, India., Kumar A; University Institute of Pharmaceutical Sciences, Punjab University, Chandigarh 160014, India., Panda JJ; Institute of Nano Science and Technology, Mohali, Punjab 140306, India. Electronic address: jyoti@inst.ac.in.
Jazyk: angličtina
Zdroj: Advances in colloid and interface science [Adv Colloid Interface Sci] 2023 Aug; Vol. 318, pp. 102954. Date of Electronic Publication: 2023 Jun 22.
DOI: 10.1016/j.cis.2023.102954
Abstrakt: Nanotherapeutics are gaining traction in the modern scenario because of their unique and distinct properties which separate them from macro materials. Among the nanoparticles, metal NPs (MNPs) have gained importance due to their distinct physicochemical and biological characteristics. Peptides also exhibit several important functions in humans. Different peptides have received approval as pharmaceuticals, and clinical trials have been commenced for several peptides. Peptides are also used as targeting ligands. Considering all the advantages offered by these two entities, the conjugation of MNPs with peptides has emerged as a potential strategy for achieving successful targeting, diagnosis, and therapy of various neurological pathologies.
Competing Interests: Declaration of Competing Interest The authors declare that they have no competing financial interests.
(Copyright © 2023 Elsevier B.V. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: